Who are the key players in North America NGS-based RNA-sequencing Market industry?

The top 5 players are Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and PerkinElmer. These companies drive innovation through advanced sequencing platforms, sample preparation solutions, and comprehensive bioinformatics. Their extensive product portfolios, strong distribution networks, and continuous investments in R&D significantly influence the North American RNA-sequencing landscape.

Which segment accounted for the largest North America NGS-based RNA-sequencing Market share?

In 2023, the research and academic institutes segment held the largest market share, owing to increased government funding and large-scale genomic studies. These organizations utilize NGS-based RNA sequencing for basic research, disease characterization, and biomarker discovery, driving significant adoption across projects and collaborations.

What are the factors driving the North America NGS-based RNA-sequencing Market?

Key market drivers include technological advancements in sequencing, increasing transcriptomics-based research, and rising prevalence of genetic disorders. Companies like Thermo Fisher Scientific continue to launch high-throughput, cost-effective NGS solutions, enabling broader accessibility and accelerating the use of RNA-sequencing across diverse applications.

Which type accounted for the largest North America NGS-based RNA-sequencing Market share?

The largest market share by type belongs to the targeted RNA sequencing segment, favored for its cost efficiency and specificity in profiling defined gene sets. Targeted RNA-seq is extensively used in disease-focused research and diagnostics, offering improved sensitivity and faster data analysis compared to whole transcriptome sequencing.

Home Healthcare

North America NGS-based RNA-sequencing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America NGS-based RNA-sequencing Market
Brand: Bussiness Insights

North America NGS-based RNA-sequencing Market: by Type (mRNA Sequencing, miRNA Sequencing, De novo Transcriptome Assembly, Small RNA Sequencing, Whole Transcriptome Sequencing, Targeted RNA Sequencing), Application (Diagnostics, Drug Discovery, Biomarker Discovery, Toxicogenomics, Personalized Medicine, Others), Distribution Channels (Direct Tenders, Retail Sales, Online Sales, Distributors & Resellers, Hospital Pharmacies, Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Pyrosequencing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20379

North America NGS-based RNA-sequencing Market, 2025-2035

The North America NGS-based RNA-sequencing market continues to evolve rapidly, driven by technological advances, expanding clinical and research applications, and growing investments in precision medicine. Increasing demand for high-throughput sequencing for genomic and transcriptomic analyses is propelling market growth across both the United States and Canada. The adoption of robust RNA-seq workflows by research institutions, clinical diagnostic labs, and biopharmaceutical companies is strengthening market share among leading players. Heightened government and private funding, alongside the introduction of next-generation platforms and automation, is expected to push overall revenue to new highs by 2035, with increasing application in drug discovery, biomarker development, and personalized medicine.

Latest Market Dynamics

Key Drivers

Rising demand for precision and personalized medicine is accelerating the adoption of NGS-based RNA-sequencing, with major companies like Illumina Inc. launching advanced sequencing solutions tailored for clinical testing and research use.

Integration of artificial intelligence and machine learning into RNA-seq workflows to enable faster bioinformatic analyses and interpretation of complex multi-omics datasets, with companies like QIAGEN leading efforts in deploying AI-driven platforms.
A shift towards single-cell RNA sequencing and spatial transcriptomics, as demonstrated through recent product launches by 10x Genomics and Pacific Biosciences, supporting higher-value applications in oncology and neurobiology.

Expansion of NGS-based RNA-sequencing applications in companion diagnostics and clinical trials represents a major opportunity, supported by partnerships between biopharma firms and sequencing providers such as Roche and Agilent Technologies.
Accelerating government and institutional investment in genomics infrastructure across the US and Canada is fostering R&D and expanding commercialization prospects for vendors like Illumina and Oxford Nanopore Technologies.

Data management and storage complexities due to the massive volume of datasets generated by next-generation RNA-sequencing remain a significant challenge, with firms like Amazon Web Services providing genomic cloud solutions but barriers to widespread adoption still exist.
Standardization of protocols and bioinformatic pipelines remains inconsistent across research and clinical labs, causing data reproducibility issues despite efforts by organizations such as the Global Alliance for Genomics & Health (GA4GH).

Among various NGS-based RNA-sequencing types, mRNA sequencing is anticipated to dominate the North America market in 2025, driven by its widespread use in gene expression profiling and disease research. This segment is closely followed by small RNA sequencing, widely adopted for miRNA and other non-coding RNA studies in functional genomics, and targeted RNA sequencing, which is gaining traction for its cost-effective approach to analyzing gene panels. The clear dominance of mRNA sequencing is a reflection of ongoing demand in both academic and clinical settings, propelling companies to launch more sensitive and scalable solutions.

Diagnostics is poised to be the leading application for NGS-based RNA-sequencing in North America by 2025, as hospitals and clinical labs increasingly incorporate transcriptomic data into oncology and rare disease diagnosis. Closely behind, drug discovery is leveraging RNA-seq for target identification and safety assessments, while biomarker discovery continues to gain momentum with a surge in translational research programs. This broadening adoption across healthcare and pharmaceutical research is expected to drive continued growth and innovation throughout the forecast period.

The North America NGS-based RNA-sequencing market is expected to exhibit steady revenue growth from 2020 through 2035, underpinned by rapid technology adoption, expanding clinical applications, and increasing R&D spending. In 2025, total market revenue is projected to reach approximately 1,350 Million USD, with a sustained annual growth rate driven by advancements in sequencing technologies, integration of automation, and higher throughput capabilities. The market is forecast to surpass 3,540 Million USD by 2035 as genetic and transcriptomic profiling become routine in both academic and clinical environments.

Year-over-year (YOY) growth in the North America NGS-based RNA-sequencing market is predicted to remain strong throughout the forecast window, peaking as new sequencers, cloud-based analysis tools, and AI-driven workflows are broadly adopted. YOY growth is expected to average around 8.3% from 2025 to 2030, gradually moderating to 5.7% by 2035 as the market matures and high-volume clinical use stabilizes in North America.

In 2025, the United States is forecast to command by far the highest regional market share for NGS-based RNA-sequencing in North America, attributed to strong research funding, advanced infrastructure, and rapid clinical adoption. Canada and Mexico are slated for steady growth, each benefiting from increased investments in genomics but at a lower volume compared to the US. The market hierarchy reflects ongoing trends in biotech innovation, healthcare implementation, and government-driven genomic research initiatives.

Illumina Inc. retains its leadership position in the North America NGS-based RNA-sequencing market for 2025, due to its commanding share of installed sequencer base and widespread adoption of its library preparation kits. Thermo Fisher Scientific and QIAGEN continue to strengthen their presence through robust consumable portfolios and data analysis solutions. This competitive landscape is marked by ongoing product innovation, strategic partnerships, and aggressive expansion tactics among major industry participants.

In North America, academic and research institutions represent the largest buyer group for NGS-based RNA-sequencing platforms and services, accounting for a substantial portion of overall demand. Clinical laboratories, driven by adoption in diagnostics and personalized medicine, form the next major segment, while pharmaceutical and biotechnology firms follow closely as they increasingly invest in RNA-seq for drug and biomarker discovery applications.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1350
Regions	US, Canada, Mexico
Segments	By Type: mRNA Sequencing, miRNA Sequencing, De novo Transcriptome Assembly, Small RNA Sequencing, Whole Transcriptome Sequencing, Targeted RNA Sequencing; By Application: Diagnostics, Drug Discovery, Biomarker Discovery, Toxicogenomics, Personalized Medicine, Others
Players	Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI, PerkinElmer Inc., Pacific Biosciences, F. Hoffmann-La Roche AG, Lexogen GmbH, Takara Bio Inc., Oxford Nanopore Technologies, Arraystar Inc., NuGEN Technologies (TECAN Group), Eurofins Scientific, Macrogen Inc.

June 2024: Illumina launched its new NovaSeq X Plus platform aimed at making high-throughput RNA-seq more accessible for clinical labs and genomic research entities across North America.
July 2024: Thermo Fisher Scientific announced an expansion of its Ion Torrent Genexus System with advanced RNA panel capabilities, supporting streamlined translational medicine workflows.
August 2024: QIAGEN introduced QIAseq Single Cell RNA-seq Kits, optimized for multi-omics integration and high-resolution transcriptomic profiling in single-cell applications.
September 2024: Pacific Biosciences partnered with leading cancer centers in the US to pilot HiFi long-read RNA sequencing in oncology diagnostics and biomarker development.
October 2024: Oxford Nanopore Technologies unveiled updated flow cells, reducing sequencing costs and turnaround times for targeted and full-length RNA profiling in North American labs.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America NGS-based RNA-sequencing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America NGS-based RNA-sequencing Market, 2025-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share (%) by Type, 2025

Market Share (%) by Application, 2025

Market Revenue (USD Million), 2020–2035

YOY Growth Rate (%), 2020–2035

Market Share (%) by Region, 2025

Market Share (%) by Leading Players, 2025

Market Share (%) by Major Buyer Groups, 2025

Study Coverage

Key Recent Developments

Frequently asked questions